F055 Our "Joint" Goal: Pearls for the Concomitant Management of Psoriasis and Psoriatic Arthritis
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Approximately 30% of patients with psoriasis also have psoriatic arthritis (PsA). Given PsA typically develops 5-10 years after the onset of psoriasis, dermatologists play a key role in helping to recognize this debilitating disease. With so many new medications approved for the treatment of both psoriasis and psoriatic arthritis, it is essential that dermatologists understand the benefits and drawbacks for each therapy. We will also look at racial and gender disparities in PsA and examine if psoriasis therapies can mitigate the development of PsA.
LEARNING OBJECTIVES
Recognize the prevalence and morbidity of untreated psoriatic arthritis in patients with psoriasis. Evaluate racial and gender disparities in PsA prevalence and disease detection.
Determine if treatment of psoriasis can prevent the development of psoriatic arthritis.
Discuss robust treatment strategies for patients with concomitant psoriasis and psoriatic arthritis and review recommendations from international psoriasis and psoriatic arthritis groups.
SCHEDULE
8:30 PM
PsA 101: Prevalence, morbidity and screening techniques
Jessica Amie Kaffenberger, MD, FAAD
9:00 PM
Worldwide pearls of Pso/PsA management from GRAPPA
Kristina Patrice Callis-Duffin, MD, FAAD
9:30 PM
Racial and gender disparities in psoriatic arthritis
Saakshi Khattri, MD, MBBS, FAAD
10:00 PM
Can psoriasis therapies prevent psoriatic arthritis?
April W. Armstrong, MD, MPH, FAAD
SPEAKERS
April W. Armstrong, MD, MPH, FAAD
Kristina Patrice Callis-Duffin, MD, FAAD
Jessica Amie Kaffenberger, MD, FAAD
Saakshi Khattri, MD, MBBS, FAAD
HANDOUTS
SPEAKER DISCLOSURES
April W. Armstrong, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Consultant(Honoraria); Boehringer Ingelheim – Data Safety Monitoring Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Consultant(Honoraria); Dermsquared – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Janssen Biotech – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Ortho Dermatologics – Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);
Kristina Patrice Callis-Duffin, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Alumis – Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria), Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Celgene Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Honoraria), Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Consultant(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding);
Jessica Amie Kaffenberger, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria); Corrona, Inc. – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding);
Saakshi Khattri, MD, MBBS, FAAD
AbbVie – Speaker(Honoraria); BMS – Investigator(Grants/Research Funding); Eli Lilly and Company – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Speaker(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria), Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding), Speaker(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); ucb – Advisory Board(Honoraria); UCB – Speaker(Honoraria);